Letrozole: In postmenopausal hormone-responsive early-stage breast cancer

Drugs

Volumn 66, Issue 3, 2006, Pages 353-362

  Scott, Lesley J ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM; CIMETIDINE; CYTOCHROME P450; LETROZOLE; PLACEBO; TAMOXIFEN; VITAMIN D; WARFARIN; ANTINEOPLASTIC AGENT; NITRILE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; BONE DENSITY; BREAST CANCER; CANCER CHEMOTHERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOUBLE ENDOMETRIAL THICKNESS; DRUG BINDING; DRUG EFFICACY; DRUG TOLERABILITY; ESTROGEN SYNTHESIS; FRACTURE; HEART FAILURE; HORMONE RESPONSE; HOT FLUSH; HUMAN; INCIDENCE; MAXIMUM PLASMA CONCENTRATION; NIGHT SWEAT; OSTEOLYSIS; POSTMENOPAUSE; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; UTERINE VOLUME; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; MALE; MIDDLE AGED; NEOPLASM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; THROMBOEMBOLISM; TRIAZOLES; VENOUS THROMBOSIS;

EID: 33646794909     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666030-00010     Document Type: Review

References (34)

1. Tobias JS. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. Int J Biochem Cell Biol 2004; 36 (11): 2112-9
2. Baum M. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control 2004; 11 (4): 217-21
3. Michaud LB. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer. Am J Health Syst Pharm 2005; 62 (3): 266-73
4. Buzdar AU. Data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clin Cancer Res 2004; 10 Suppl. 1: 355-361s
5. Smith IE. Aromatase inhibitors: extending the benefits of adjuvant therapy beyond tamoxifen. Breast 2004; 13 Suppl. 1: S3-9
6. Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs 2004; 64 (11): 1213-30
7. Lamb HM, Adkins JC. Letrozole: a review of its use in postmenopausal women with advanced beast cancer. Drugs 1998; 56 (6): 1125-40
8. Keating GM, Jarvis B. Letrozole: an updated review of its use in postmenopausal women with advanced breast cancer. Am J Cancer 2002; 1 (5): 351-71
9. Haynes BP, Dowsett M, Miller WR, et al. The pharmacology of letrozole. J Steroid Biochem Mol Biol 2003; 87 (1): 35-45
10. Bajetta E, Zilembo N, Bichisao E. Aromatase inhibitors in the treatment of postmenopausal breast cancer. Drugs Aging 1999; 15 (4): 271-83
11. Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 2003; 9 Suppl.: 468-472S
12. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20 (3): 751-7
13. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003; 63 (19): 6523-31
14. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women completing ≥5 years (yrs) of adjuvant tamoxifen: NCIC CTG MA.17B [abstract no. 404]. Breast Cancer Res Treat 2004; 88 Suppl. 1: S36
15. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005; 16 (5): 707-15
16. Morales L, Timmerman D, Neven P, et al. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 2005; 16 (1): 70-4
17. Lonning PE. Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clin Pharmacokinet 2003; 42 (7): 619-31
18. Sioufi A, Sandrenan N, Godbillon J, et al. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration. Biopharm Drug Dispos 1997; 18 (6): 489-97
19. Pfister CU, Martoni A, Zamagni C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 2001; 22 (5): 191-7
20. Novartis. Femara® (letrozole tablets) prescribing information (US) [online]. Available from URL: www.us.femara.com/info/page/prescribing [Accessed 2005 Feb 18]
21. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 2006; 353 (26): 2747-57
22. Viale G, Regan M, Dell'Orto P, et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract no. 44]. 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio, TX
23. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97 (17): 1262-71
24. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349 (19): 1793-802
25. Mann BS, Johnson JR, Kelly R, et al. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res 2005; 11 (16): 5671-7
26. Goss PE, on behalf of MA.17 Collaborative Trialists. NCIC CTG MA.17: updated analysis post-unblinding [abstract plus oral presentation]. 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio, TX
27. Ingle J, Goss P, Tu D, et al. NCIC CTC MA.17: increasing benefit of letrozole with longer duration of treatment as measured by the hazard ratio of disease recurrence over time [abstract plus oral presentation]. 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio, TX
28. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23 (28): 6931-40
29. Dunn C, Keam SJ. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. Pharmacoeconomics 2006; 24. In press
30. Laforte M-E. Novartis' Femara receives expanded approval from FDA [online]. Available from URL: http://www.firstwordplus.com [Accessed 2006 Jan 9]
31. Novartis. UK leads Europe and US in milestone post-op breast cancer treatment decision [media release] [online]. Available from URL: http://www.novartis.com [Accessed 2005 Dec 12]
32. Novartis. Comparison trial of letrozole to anastrozole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer [online]. Available from URL: http://clinicaltrials.gov/show/NCT00248170 [Accessed 2006 Jan 20]
33. Novartis Pharmaceuticals Canada Inc. Health Canada approves first and only breast cancer treatment that improves disease-free survival beyond five years of diagnosis [media release] [online]. Available from URL: http://www.novartis.ca [Accessed 2005 Apr 21]
34. Novartis. Femara® approved in Germany as the only hormonal therapy given after standard tamoxifen for post-menopausal woman with early breast cancer [media release] [online]. Available from URL: http://www.novartis.com [Accessed 2005 Mar 15]